QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.103.056929v1 309/1/398    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jerde, T. J. Articles by Nakada, S. Y. Search for Related Content PubMed PubMed Citation Articles by Jerde, T. J. Articles by Nakada, S. Y.

INFLAMMATION AND IMMUNOPHARMACOLOGY

Suppression of 15-Hydroxyprostaglandin Dehydrogenase Messenger RNA Concentration, Protein Expression, and Enzymatic Activity during Human Ureteral Obstruction

Uropharmacology and Endourology Research Laboratory, Department of Surgery, Division of Urology, University of Wisconsin Medical School, Madison, Wisconsin (T.J.J., D.E.B., S.Y.N.); Department of Pharmaceutical Sciences, University of Wisconsin School of Pharmacy, Madison, Wisconsin (T.J.J., W.S.M.); Department of Carcinogenesis, University of Texas MD Anderson Cancer Center, Smithville, Texas (S.M.F.); and Office of Education, American Urological Association, Baltimore, Maryland (M.L.)

Prostanoids produce significant effects in the ureter, particularly in response to obstruction. Ureteral obstruction is associated with increased prostanoid synthesis via cyclooxygenase induction; however, prostaglandin degradation mediated by 15-hydroxyprostaglandin dehydrogenase (PGDH) has not been evaluated in the ureter. The purpose of this study was to determine whether PGDH steady-state mRNA, protein, and enzyme activity are altered in the human ureter during obstruction. Human ureteral segments from patients undergoing donor nephrectomy (normal segments) or ureteral stricture repair (obstructed segments) were obtained with proper informed consent. We evaluated PGDH steady-state mRNA relative to ribosomal protein S26 reference gene by reverse transcription-polymerase chain reaction and Vistra Green fluoroimaging. We determined PGDH protein content relative to glyceraldehyde-3-phosphate dehydrogenase by immunoblotting and PGDH localization by immunohistochemistry. PGDH enzymatic activity was determined by measurement of conversion of 15-hydroxy- to 15-keto-prostaglandin using thin layer chromatography separation. We found that PGDH mRNA and protein were decreased 4- to 6-fold, and enzyme activity was decreased >3-fold in obstructed human ureter relative to normal controls. PGDH was localized to the urothelial cells, with little or no expression in smooth muscle. Our results indicate that PGDH mRNA, protein, and enzyme activity are suppressed in the human ureter during obstruction. Increased concentrations of prostanoids subsequent to ureteral obstruction seem to be due to decreased degradation as well as increased synthesis. Modulation of prostanoid degradation may have therapeutic relevance in obstructive disorders of the ureter.

Address correspondence to: Dr. Stephen Y. Nakada, Department of Surgery, Division of Urology, G5/339 Clinical Science Center, 600 Highland Ave., University of Wisconsin Medical School, Madison, WI 53792. E-mail: nakada{at}surgery.wisc.edu

This article has been cited by other articles:

				P. Rastogi, A. Rickard, N. Dorokhov, D. J. Klumpp, and J. McHowat Loss of prostaglandin E2 release from immortalized urothelial cells obtained from interstitial cystitis patient bladders Am J Physiol Renal Physiol, May 1, 2008; 294(5): F1129 - F1135. [Abstract] [Full Text] [PDF]